Company Overview

Update
Founded:
2004
Headquarters:
Seattle, WA
Funding:
$27.10M
Categories:
Biotechnology

Theraclone Sciences is a biotech company developing novel therapeutic antibodies for the treatment of infectious diseases and inflammation.

Description

Update

Theraclone Sciences is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company’s technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

Current Team (5)

Update

Board Members and Advisors (3)

Update

Funding Rounds (4) - $27.10M

Update

Investors (10)

Update

Offices/Locations (1)

Update
  • Office

    Seattle Life Sciences Building

    1124 Columbia Street, Suite 300

    Seattle, WA 98104

    USA